Ключевые слова:
рак щитовидной железы; иммунология; микроокружение опухоли; цитокины; интерлейкины; биомаркеры; метастазирование.Библиографические ссылки
1. Иванов В.К. Динамика заболеваемости раком щитовидной железы населения России: основные факторы риска / В.К. Иванов, А.И. Горский, В.В. Полькин и др. // Радиация и риск. — 2022. — 4.
2. Кухтенко Ю.В. Структура заболеваний щитовидной железы у пациентов различных возрастных групп / Ю.В. Кухтенко, А.М. Шулутко, В.И. Семиков и др. // Вестник ВолгГМУ. — 2016. — 59.
3. Шулутко А.М., Семиков В.И., Грязнов С.Е., и др. Клиническое значение, диагностика и лечение дифференцированной микрокарциномы ЩЖ. // Хирургия. Журнал им. Н.И. Пирогова. – 2007. - №12 – C.1-15.
4. Almubarak, AA ∙ Albkiry, YA ∙ Alsalem, AA ∙ et al. The association of low socioeconomic status with advanced stage thyroid cancer. J Taibah Univ Med Sci. 2021; 16:482-490
5. Baker KJ, Houston A, Brint E. IL-1 family members in cancer; two sides to every story. Front Immunol. (2019) 10:1197. doi: 10.3389/fimmu.20 19.01197
6. Beatty, G.L.; Gladney, W.L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 2015, 21, 687–692.
7. Cao, XJ ∙ Wang, SR ∙ Che, Y ∙ et al. Efficacy and safety of thermal ablation for treatment of solitary T1N0M0 papillary thyroid carcinoma: a multicenter retrospective study. Radiology. 2021; 300: 209-216
8. Carvalho DFG, Zanetti BR, Miranda L, Hassumi-Fukasawa MK, Miranda-Camargo F, Crispim JCO, et al. High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol Lett. (2017) 13:1925–31.
9. Cunha LL, Morari EC, Nonogaki S, Marcello MA, Soares FA, Vassallo J, et al. Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer. Cancer Immunol Immunother. (2017) 66:141–8. doi: 10.1007/s00262-016-1924-4
10. Cunha, L.L.; Marcello, M.A.; Nonogaki, S.; Morari, E.C.; Soares, F.A.; Vassallo, J.; Ward, L.S. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clin. Endocrinol. 2015, 83, 246–253.
11. Dossus L, Franceschi S, Biessy C, Navionis AS, Travis RC, Weiderpass E, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. Int J Cancer. (2018) 142:1332–42.
12. Durante, C ∙ Costante, G ∙ Lucisano, G ∙ et al. The natural history of benign thyroid nodules. JAMA. 2015; 313:926-935
13. Fallahi, P.; Ferrari, S.M.; Piaggi, S.; Luconi, M.; Cantini, G.; Gelmini, S.; Elia, G.; Ruffilli, I.; Antonelli, A. The paramount role of cytokines and chemokines in papillary thyroid cancer: A review and experimental results. Immunol. Res. 2018, 66, 710–722.
14. Galdiero, M.R.; Garlanda, C.; Jaillon, S.; Marone, G.; Mantovani, A. Tumor associated macrophages and neutrophils in tumor progression. J. Cell Physiol. 2013, 228, 1404–1412.
15. Galdiero, M.R.; Varricchi, G.; Loffredo, S.; Mantovani, A.; Marone, G. Roles of neutrophils in cancer growth and progression. J. Leukoc. Biol. 2018, 103, 457–464.
16. Jablonska, J.; Leschner, S.; Westphal, K.; Lienenklaus, S.; Weiss, S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Investig. 2010, 120, 1151–1164.
17. Janas, M.L.; Groves, P.; Kienzle, N.; Kelso, A. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J. Immunol. 2005, 175, 8003–8010.
18. Jang, J.E.; Hajdu, C.H.; Liot, C.; Miller, G.; Dustin, M.L.; Bar-Sagi, D. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates antitumor immunity in pancreatic cancer. Cell Rep. 2017, 20, 558–571.
19. Martins MB, Marcello MA, Batista FA, Peres KC, Meneghetti M, Ward MAL, et al. Serum interleukin measurement may help identify thyroid cancer patients with active disease. Clin Biochem. (2017) 52:1–7.
20. Muzza, M.; Degl’Innocenti, D.; Colombo, C.; Perrino, M.; Ravasi, E.; Rossi, S.; Cirello, V.; Beck-Peccoz, P.; Borrello, M.G.; Fugazzola, L. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: Clinical and molecular studies. Clin. Endocrinol. 2010, 72, 702–708.
21. Ryder, M.; Ghossein, R.A.; Ricarte-filho, J.C.; Knauf, J.A.; Fagin, J.A. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 2008, 15, 1069–1074.
22. Scapini, P.; Cassatella, M.A. Social networking of human neutrophils within the immune system. Blood 2014, 124, 710–719.
23. Teng, F.; Meng, X.; Kong, L.; Mu, D.; Zhu, H.; Liu, S.; Zhang, J.; Yu, J. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl. Res. 2015, 166, 721–732.
24. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. Immunity. 2018, 48, 812–830.
25. Tran Janco, J.M.; Lamichhane, P.; Karyampudi, L.; Knutson, K.L. Tumor-infiltrating dendritic cells in cancer pathogenesis. J. Immunol. 2015, 194, 2985–2991.
26. Varricchi, G.; Harker, J.; Borriello, F.; Marone, G.; Durham, S.R.; Shamji, M.H. T follicular helper (Tfh) cells in normal immune responses and in allergic disorders. Allergy. 2016, 71, 1086–1094.
27. Zhao, S.G.; Lehrer, J.; Chang, S.L.; Das, R.; Erho, N.; Liu, Y.; Sjöström, M.; Den, R.B.; Freedland, S.J.; Klein, E.A.; et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J. Natl. Cancer Inst. 2019, 111, 301–310.